• Explore /
  • Poster
  • / FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

Abstract Poster

Authors

null

Evelyne Lopez-Crapez

Institut régional du Cancer de Montpellier ICM, Montpellier, France

Evelyne Lopez-Crapez , Antoine Adenis , Simon Thezenas , Eric Assenat , Eric Francois , Rosine Guimbaud , Marion Chauvenet , Faiza Khemissa , Franck Audemar , Etienne Suc , Michel Rivoire , François Ghiringhelli , Anne Mercier-Blas , Laurent Mineur , Yves Becouarn , Philippe Houyau , Trevor Stanbury , Claire Jouffroy-Zeller , Olivier Bouche , Marc Ychou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01442935

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3548)

DOI

10.1200/JCO.2018.36.15_suppl.3548

Abstract #

3548

Poster Bd #

41

Abstract Disclosures

Similar Posters

First Author: Marc Ychou

First Author: Chiara Cremolini

First Author: Emmanuelle Samalin

First Author: Valerie Boige